Kiniksa Corp (KNSA) - Long-Term Debt to Capital Coefficient
Kiniksa Pharmaceuticals is developing therapies for orphan diseases through partnerships with scientific centers, testing agents to correct immune malfunctions. The business's environmental profile is standard and limited to the disposal of laboratory waste. The model relies on a comprehensive approach to treating cardiovascular and autoimmune disorders (Arcalyst), where the indicator is 0.01. The price trajectory shown below visualizes the market dynamics of this biopharmaceutical asset.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_KNSA_-_Kiniksa-Pharmaceuticals_-_Long-Term-Debt-to-Capital "KNSA: Kiniksa Long-Term Debt to Capital 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Kiniksa Pharmaceuticals (KNSA)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:Kiniksa Pharmaceuticals, Ltd. - KNSA
This indicator measures the proportion of credit obligations with a maturity of more than one year relative to equity, reflecting the company's dependence on debt financing. Analyzing the ratio of long-term debt to net assets allows for an assessment of the risks associated with Kiniksa Pharmaceuticals (KNSA) expanding into targeted immunology and scaling the Arcalyst distribution network, revealing the balance between aggressive growth and financial stability.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital biocryst.com|Long-Term Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PHVS (Pharvaris Corp)|Ratio of Long-Term Indebtedness to Capital AbCellera (ABCL)|TRML - Long-Term Debt to Equity|precigen.com (PGEN) - Long-Term Debt to Equity Ratio|Pharming Group (PHAR) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Nektar Therapeutics Inc|Long-Term Debt to Equity Ratio UPB|Long-Term Debt to Capital Zenas Corp|Long-Term Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|PVLA - Long-Term Debt to Equity|SVRA - Long-Term Debt to Capital|RIGL: Long-Term Debt to Capital|ANAB - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Astria Therapeutics, Inc.|Long-Term Debt to Capital Ratio ENGN (enGene Holdings Inc)|Long-Term Debt to Capital RAPT|Ratio of Long-Term Indebtedness to Capital aerovatetx.com|Long-Term Debt to Equity Aclaris Therapeutics ACRS|Long-Term Debt to Capital kyvernatx.com KYTX|TLSA - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Cabaletta Bio Inc. CABA|VTYX: Long-Term Debt to Capital|Theratechnologies, Inc (THTX) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio AVTX|ELDN: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Agenus Inc. (AGEN)|CLYM: Long-Term Liabilities to Equity|Long-Term Debt to Capital ZURA (Zura Bio Limited)|Long-Term Debt to Capital Coefficient ATYR|Adagene Corp - Long-Term Debt to Capital|IMA - Long-Term Debt to Capital|shattucklabs.com (STTK) - Long-Term Debt to Equity|Equillium - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Connect Biopharma Holdings|Long-Term Debt to Equity Ratio Immunic Inc (IMUX)|Long-Term Debt to Capital ATRA|Long-Term Debt to Capital inflarx.de (IFRX)|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|ACET - Long-Term Debt to Equity Ratio|Celularity Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital INmune Bio Corporation|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Equity Ratio|kezarlifesciences.com (KZR) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio SABS|AKTX (Akari Therapeutics PLC) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital ENLV|Ratio of Long-Term Indebtedness to Capital q32bio.com|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|EDSA - Long-Term Debt to Equity Ratio|iBio - Long-Term Debt to Capital|CARM - Long-Term Debt to Capital|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|BOLT (Bolt Biotherapeutics, Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity HCW Biologics, Inc.|Aptevo (APVO) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity AIM ImmunoTech (AIM)|Long-Term Debt to Capital aditxt.com (ADTX)|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX: Long-Term Debt to Capital Ratio|HIND - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital revbiosciences.com REVB|INDP: Long-Term Debt to Capital|Scinai Immunotherapeutics Ltd (SCNI) - Long-Term Debt to Capital|Long-Term Debt to Equity CalciMedica Inc|Affimed Therapeutics - Long-Term Liabilities to Equity|Long-Term Debt to Capital ALLK|HOOK (hookipapharma.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|OCEA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient TCBP (TC BioPharm Ltd)|Third Harmonic Bio (THRD) - Long-Term Debt to Equity